# A Comparison of SLx-4090 in Combination With Metformin Versus Metformin Therapy Alone in Patients With Type 2 Diabetes

> **NCT00871936** · PHASE2 · COMPLETED · sponsor: **Response Pharmaceuticals** · enrollment: 82 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** SLx-4090
- **OTHER:** Placebo
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT00871936
- **Lead sponsor:** Response Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00871936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00871936, "A Comparison of SLx-4090 in Combination With Metformin Versus Metformin Therapy Alone in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00871936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*